| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2022 | 842.76% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 07/29/2022 | 1044.78% | Chardan Capital | $15 → $17 | Maintains | Buy |
| 03/16/2022 | 1112.12% | Chardan Capital | $17 → $18 | Maintains | Buy |
| 11/24/2021 | 1044.78% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/10/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
What is the target price for Better Therapeutics (BTTX)?
The latest price target for Better Therapeutics (NASDAQ: BTTX) was reported by Chardan Capital on November 15, 2022. The analyst firm set a price target for $14.00 expecting BTTX to rise to within 12 months (a possible 842.76% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Better Therapeutics (BTTX)?
The latest analyst rating for Better Therapeutics (NASDAQ: BTTX) was provided by Chardan Capital, and Better Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Better Therapeutics (BTTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Better Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Better Therapeutics was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
Is the Analyst Rating Better Therapeutics (BTTX) correct?
While ratings are subjective and will change, the latest Better Therapeutics (BTTX) rating was a maintained with a price target of $17.00 to $14.00. The current price Better Therapeutics (BTTX) is trading at is $1.49, which is out of the analyst's predicted range.